Quantification of rare NPM1 mutation subtypes by digital PCR

British Journal of Haematology

Volumn 167, Issue 5, 2014, Pages 710-714

  Bacher, Ulrike ^a   Dicker, Frank ^a   Haferlach, Claudia ^a   Alpermann, Tamara ^a   Rose, Dominic ^a   Kern, Wolfgang ^a   Haferlach, Torsten ^a   Schnittger, Susanne ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

Digital PCR; Minimal residual disease (MRD); Rare NPM1 mutation subtypes; Real time PCR

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA; NUCLEOPHOSMIN; NUCLEAR PROTEIN; TUMOR PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; ANALYTICAL EQUIPMENT; COHORT ANALYSIS; COMPUTER PROGRAM; CONTROLLED STUDY; DIGITAL POLYMERASE CHAIN REACTION; EVENT FREE SURVIVAL; FOLLOW UP; GENETIC ANALYZER; HUMAN; INTERMETHOD COMPARISON; LETTER; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MONONUCLEAR CELL; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE REAL TIME POLYMERASE CHAIN REACTION; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SENSITIVITY AND SPECIFICITY; SIGNAL DETECTION; ACUTE GRANULOCYTIC LEUKEMIA; FEMALE; GENETICS; MALE; MUTATION; NUCLEOTIDE SEQUENCE; PROCEDURES; STANDARDS;

DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MUTATION; NEOPLASM PROTEINS; NUCLEAR PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84925226324     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13038     Document Type: Letter

References (10)

1. Alpermann, T., Haferlach, C., Dicker, F., Eder, C., Kohlmann, A., Kern, W., Haferlach, T. & Schnittger, S. (2013) Evaluation of different NPM1 mutations in AML patients according to clinical, cytogenetic and molecular features and impact on outcome. Blood, 122, 51a.
2. Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., Bigerna, B., Pacini, R., Pucciarini, A., Liso, A., Vignetti, M., Fazi, P., Meani, N., Pettirossi, V., Saglio, G., Mandelli, F., Lo-Coco, F., Pelicci, P.G. & Martelli, M.F. (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. New England Journal of Medicine, 352, 254-266.
3. Gorello, P., Cazzaniga, G., Alberti, F., Dell'Oro, M.G., Gottardi, E., Specchia, G., Roti, G., Rosati, R., Martelli, M.F., Diverio, D., Lo, C.F., Biondi, A., Saglio, G., Mecucci, C. & Falini, B. (2006) Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia, 20, 1103-1108.
4. Krönke, J., Schlenk, R.F., Jensen, K.O., Tschurtz, F., Corbacioglu, A., Gaidzik, V.I., Paschka, P., Onken, S., Eiwen, K., Habdank, M., Spath, D., Lubbert, M., Wattad, M., Kindler, T., Salih, H.R., Held, G., Nachbaur, D., von Lilienfeld-Toal, M., Germing, U., Haase, D., Mergenthaler, H.G., Krauter, J., Ganser, A., Gohring, G., Schlegelberger, B., Dohner, H. & Dohner, K. (2011) Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. Journal of Clinical Oncology, 29, 2709-2716.
5. Oehler, V.G., Qin, J., Ramakrishnan, R., Facer, G., Ananthnarayan, S., Cummings, C., Deininger, M.W., Shah, N., McCormick, F., Willis, S., Daridon, A., Unger, M. & Radich, J.P. (2009) Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR. Leukemia, 23, 396-399.
6. Schnittger, S., Schoch, C., Dugas, M., Kern, W., Staib, P., Wuchter, C., Loffler, H., Sauerland, C.M., Serve, H., Buchner, T., Haferlach, T. & Hiddemann, W. (2002) Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood, 100, 59-66.
7. Schnittger, S., Schoch, C., Kern, W., Mecucci, C., Tschulik, C., Martelli, M.F., Haferlach, T., Hiddemann, W. & Falini, B. (2005) Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood, 106, 3733-3739.
8. Schnittger, S., Kern, W., Tschulik, C., Weiss, T., Dicker, F., Falini, B., Haferlach, C. & Haferlach, T. (2009) Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood, 114, 2220-2231.
9. Shayegi, N., Kramer, M., Bornhauser, M., Schaich, M., Schetelig, J., Platzbecker, U., Rollig, C., Heiderich, C., Landt, O., Ehninger, G. & Thiede, C. (2013) The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. Blood, 122, 83-92.
10. Thol, F., Kolking, B., Damm, F., Reinhardt, K., Klusmann, J.H., Reinhardt, D., von, N.N., Brugman, M.H., Schlegelberger, B., Suerbaum, S., Krauter, J., Ganser, A. & Heuser, M. (2012) Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations. Genes, Chromosomes & Cancer, 51, 689-695.